Eton Pharmaceuticals (ETON) Interest & Investment Income (2018 - 2019)
Eton Pharmaceuticals (ETON) reported Interest & Investment Income of $77000.0 for Q3 2019, up 208.0% on a YoY basis from $25000.0 in Q3 2018, and down 23.0% sequentially from $100000.0 in Q2 2019.
Eton Pharmaceuticals (ETON) Interest & Investment Income (2018 - 2019) Analysis & Trends
Eton Pharmaceuticals (ETON) has 2 years of Interest & Investment Income data on file, last reported at $77000.0 in Q3 2019.
- For the quarter ending Q3 2019, Interest & Investment Income rose 208.0% year-over-year to $77000.0; the trailing twelve-month figure through Sep 2019 stood at $403000.0 (changed N/A YoY), and the FY2018 full-year result was $164000.0, up 368.57% from the prior year.
- Interest & Investment Income fell to $77000.0 in Q3 2019, from $100000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $144000.0 in Q1 2019 to a low of $25000.0 in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 32.85 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 41.80 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 28.10 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Eton Pharmaceuticals | 1.14 Bn | 1.11 Bn | 13.10 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 77,000.00 |
| Jun 30, 2019 | 100,000.00 |
| Mar 31, 2019 | 144,000.00 |
| Dec 31, 2018 | 82,000.00 |
| Sep 30, 2018 | 25,000.00 |
| Jun 30, 2018 | 28,000.00 |
| Mar 31, 2018 | 29,000.00 |